Dan Theodorescu MD PhD is a physician scientist who has devoted his career to the study of bladder cancer. His pioneering application of computational biology led to the discovery of genes that drive growth and metastasis, while providing novel biomarkers and therapeutic targets and foundations for precision medicine such as the Molecular Twin Precision Oncology Platform and the COXEN principle. He led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic now licensed by pharma, and identified approaches that define effective combination therapy with checkpoint inhibitors. Recently, he was the first to demonstrate that loss of the Y chromosome in cancer makes tumors more aggressive by immune system evasion. Theodorescu is a founding co-editor in chief of Bladder Cancer, the only journal focused on this disease. He is a member of ASCI, AAP, National Academy of Medicine and a fellow of AAAS.